Project Acronym: TargetedResponse
Project title: Functional diagnostics in non-small cell lung carcinoma – a new concept for the improvement of personalized therapy in Serbian patients
Project ID/Number: 7739737
Project PI and Coordinating Institution: Dr Milica Pešić, Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade (IBISS)
Funding Institution: Science Fund of the Republic of Serbia
Call Information: IDEAS
Fields of Science: (Bio)medical Sciences
Consortium/Participating Institutions: Institute for Biological Research "Siniša Stanković" – National Institute of Republic of Serbia, University of Belgrade (IBISS) and Faculty of Medicine-University of Belgrade (MFUB)
Grant Duration: 31. January 2022 – 30. January 2025
Budget: 386.191.13 €
Project Abstract:
TargetedResponse project will implement a novel person-centered approach based on functional diagnostics to determine the optimal treatment strategy for Serbian non-small cell lung carcinoma (NSCLC) patients. This approach combines the treatment response of patient-derived cancer cells with their genetic profile. The rationale for using this concept is due to the small portion of targeted therapy responders classified only according to their molecular alterations. Serbia has the second-highest incidence in Central and Southeastern Europe with 76.4 new cases of NSCLC per 100,000 inhabitants diagnosed each year. Comprehensive analyses of data for NSCLC molecular markers in the Serbian population have never been performed and many approved targeted therapeutics for NSCLC are not available and reimbursable in Serbia. To achieve its objectives, TargetedResponse will use the following methods: NSCLC patients’ sample and data collection; histopathological examination; DNA isolation and Whole Exome Sequencing (WES); establishment of patient-derived primary cell cultures; development of the immunoassay to distinguish cancer from non-cancer cells and to evaluate the expression of the multidrug resistance (MDR) markers; ex vivo testing of tyrosine kinase inhibitors (TKIs); comparison of the ex vivo results with molecular alterations; interpretation of results and their translation from bench to patients. TargetedResponse expects to identify the most reliable molecular markers and targeted therapies for NSCLC patients in Serbia. Besides, TargetedResponse will determine whether the MDR phenotype can be induced with targeted therapy and thus make valuable recommendations for the oncologists. TargetedResponse results should serve as a guidance tool for the personalized therapy of NSCLC patients particularly influencing healthcare in Serbia. However, the applicative potential of TargetedResponse results will have a more general impact on the scientific community.
Website: targetedresponse.ibiss.bg.ac.rs
Social Network IDs:
www.facebook.com
www.linkedin.com
www.x.com
www.instagram.com
Contact for Collaborations:
targetedresponse2022@gmail.com
Graphical abstract: